Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cogent Biosciences, Inc. Market Cap
From what 11 stock analysts predict, the share price for Cogent Biosciences, Inc. (COGT) might increase by 84.07% in the next year. This is based on a 12-month average estimation for COGT. Price targets go from $10 to $23. The majority of stock analysts believe COGT is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Cogent Biosciences, Inc. has a total of 11 Wall St Analyst ratings. There are 9 buy ratings, 2 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Cogent Biosciences, Inc. will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of COGT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Anupam Rama JP Morgan | Overweight | $21 | Maintains | Nov 14, 2024 |
| Ami Fadia Needham | Buy | $15 | Maintains | Nov 13, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $17 | Reiterates | Nov 4, 2024 |
| Ami Fadia Needham | Buy | $16 | Reiterates | Oct 24, 2024 |
| David Lebowitz Citigroup | Buy | $15 | Maintains | Sep 24, 2024 |
| Joel Beatty Baird | Neutral | $10 | Maintains | Sep 5, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $17 | Maintains | Sep 3, 2024 |
| Anupam Rama JP Morgan | Overweight | $19 | Maintains | Aug 7, 2024 |
| Ami Fadia Needham | Buy | $18 | Reiterates | Aug 7, 2024 |
| Ami Fadia Needham | Buy | $18 | Reiterates | Jun 27, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $19 | Reiterates | Jun 17, 2024 |
| Ami Fadia Needham | Buy | $18 | Reiterates | Jun 17, 2024 |
| David Nierengarten Wedbush | Neutral | $10 | Reiterates | May 24, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $19 | Reiterates | May 13, 2024 |
| Ami Fadia Needham | Buy | $18 | Reiterates | May 8, 2024 |
| Anupam Rama JP Morgan | Overweight | $20 | Maintains | Feb 27, 2024 |
| David Lebowitz Citigroup | Buy | $13 | Maintains | Feb 26, 2024 |
| Ami Fadia Needham | Buy | $18 | Reiterates | Feb 26, 2024 |
| Joel Beatty Baird | Neutral | $8 | Downgrade | Feb 26, 2024 |
| David Nierengarten Wedbush | Neutral | $10 | Maintains | Feb 23, 2024 |
When did it IPO
2020
Staff Count
164
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Andrew R. Robbins M.B.A.
Market Cap
$997.5M
In 2023, COGT generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that COGT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 28 Jun 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Cogent (COGT) reported a positive FDA meeting regarding MS2D2, a new patient-reported outcome measure for the SUMMIT study, leading to an increase in the company's share price.
Why It Matters - Cogent's positive FDA meeting boosts confidence in its MS2D2 outcome measure, potentially enhancing SUMMIT study results and driving share value. Positive regulatory feedback often signals growth potential.
Fri, 14 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Bezuclastinib at 100 mg significantly reduced severe symptoms and mast cell reactions in patients, indicating potential therapeutic benefits.
Why It Matters - Positive results for bezuclastinib suggest potential market success, impacting company valuations and stock performance in the biotech sector.
Thu, 23 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cogent Biosciences reported positive lead-in data from its Phase 3 PEAK trial for bezuclastinib in GIST patients. A new Phase 2 trial is also underway, with results to be presented at ASCO on June 1.
Why It Matters - Positive Phase 3 trial results for bezuclastinib enhance Cogent Biosciences' growth potential, attract investment interest, and could influence stock performance amid rising confidence in new therapies for GIST.
Thu, 23 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cogent Biosciences appointed Cole Pinnow as Chief Commercial Officer, focusing on commercial strategy and preparing for the potential launch of bezuclastinib for systemic mastocytosis and GIST.
Why It Matters - The appointment of Cole Pinnow as CCO signals Cogent's focus on commercializing bezuclastinib, enhancing growth potential and investor confidence in upcoming product launches.
Tue, 07 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - SUMMIT, PEAK, and APEX clinical trials are on schedule, with topline results anticipated in 2025.
Why It Matters - Timely enrollment and upcoming topline results from key trials in 2025 indicate potential growth catalysts, influencing market sentiment and investment decisions in related sectors.
Thu, 18 Apr 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Purcell & Lefkowitz LLP is investigating Cogent Biosciences, Inc. (NASDAQ: COGT) for potential breaches of fiduciary duty by its directors regarding recent corporate actions.
Why It Matters - The investigation into Cogent Biosciences' directors for potential fiduciary breaches could lead to legal repercussions, affecting share value and investor confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
